We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CGF:ASXChallenger Limited Analysis

Data as of 2026-03-14 - not real-time

A$7.38

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Challenger Limited is trading well below its intrinsic valuation, with the market price far under the discounted cash flow estimate. The price‑earnings multiple sits comfortably beneath the sector average, indicating a valuation gap. A robust dividend yield combined with a payout ratio under half suggests the dividend is sustainable. Operating margins remain strong, delivering healthy profitability despite a recent dip in revenue. The balance sheet shows ample cash relative to debt, providing a solid liquidity cushion. Recent earnings commentary highlighted record annuity sales, underscoring growth momentum in core businesses.
Technical indicators point to oversold conditions, as reflected by a low RSI and a bearish MACD divergence. The stock is hovering near a key support level, while the 20‑day moving average lies above the current price, suggesting limited upside in the immediate term. Low beta indicates limited systematic risk, even though recent price swings have been volatile. The sector faces moderate regulatory scrutiny, and the company’s multinational footprint adds geographic diversification. A potential private‑equity takeover could reshape the capital structure and affect valuation dynamics. Overall, the combination of deep discount, solid fundamentals, and attractive yield makes the stock a compelling candidate for investors with a medium to long horizon.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • oversold technical signals
  • proximity to support level
  • potential takeover uncertainty

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • significant valuation discount
  • strong cash generation
  • attractive dividend yield

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • sustainable earnings profile
  • low systematic risk
  • ongoing growth in annuity sales

Key Metrics & Analysis

Financial Health

Revenue Growth-16.90%
Profit Margin16.39%
P/E Ratio11.9
ROE11.55%
ROA2.43%
Debt/Equity195.79
P/B Ratio1.2
Op. Cash FlowA$1.9B
Free Cash FlowA$1.0B
Industry P/E16.4

Technical Analysis

TrendNeutral
RSI27.3
SupportA$7.25
ResistanceA$9.24
MA 20A$8.36
MA 50A$8.84
MA 200A$8.63
MACDBearish
VolumeStable
Fear & Greed Index72.88

Valuation

Fair ValueA$35.58
Target PriceA$9.44
Upside/Downside27.91%
GradeUndervalued
TypeBlend
Dividend Yield4.20%

Risk Assessment

Beta0.32
Volatility45.01%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.